$CNTA
Centessa Pharmaceuticals plc Stock $cnta

$cnta Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000184790322000022 Filed on March 30, 2022

Income Statement

Concept	2021 Q4	2021 Q1	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.99M	$8.213M	$42.89M
YoY Change	4116.88%	2044.39%	3665.41%
% of Gross Profit
Research & Development	$41.53M	$662.0K	$95.66M
YoY Change	1440.01%	-76.43%	928.49%
% of Gross Profit
Depreciation & Amortization	$12.00K	$2.000K	$34.00K
YoY Change
% of Gross Profit
Operating Expenses	$58.29M	$662.0K	$153.6M
YoY Change	1839.83%	-79.26%	1551.76%
Operating Profit		-$783.0K
YoY Change
Interest Expense	-$1.272M	-$9.000K	-$1.172M
YoY Change	542.42%	-43.75%	1623.53%
% of Operating Profit
Other Income/Expense, Net	-$1.096M	$0.00	-$5.701M
YoY Change	1189.41%	-100.0%	-3778.06%
Pretax Income	-$60.66M	-$829.0K	-$381.0M
YoY Change	1746.01%	-72.47%	3472.7%
Income Tax	$114.0K	$0.00	$114.0K
% Of Pretax Income
Net Earnings	-$60.77M	-$829.0K	-$381.1M
YoY Change	469.95%	-72.47%	3473.77%
Net Earnings / Revenue
Basic Earnings Per Share		-$4.97
Diluted Earnings Per Share	-$661.5K	-$4.97	-$5.070M
COMMON SHARES
Basic Shares Outstanding	89.90M shares	48.05M shares
Diluted Shares Outstanding		48.05M shares

Balance Sheet

Concept	2021 Q4	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$595.1M	$298.6M	$595.1M
YoY Change			8134.15%
Cash & Equivalents	$595.1M	$6.258M
Short-Term Investments
Other Short-Term Assets	$993.0K	$2.070M	$16.88M
YoY Change	16450.0%		1576.07%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$628.8M	$313.6M	$628.8M
YoY Change	5531.65%		5531.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$162.0K	$45.00K	$162.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$699.0K	$6.839M	$699.0K
YoY Change	26.63%
Total Long-Term Assets	$861.0K	$6.884M	$861.0K
YoY Change	55.98%		55.98%
TOTAL ASSETS
Total Short-Term Assets	$628.8M	$313.6M	$628.8M
Total Long-Term Assets	$861.0K	$6.884M	$861.0K
Total Assets	$629.6M	$320.5M	$629.6M
YoY Change	5273.69%		5273.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.065M	$12.22M	$8.065M
YoY Change	681.49%		681.49%
Accrued Expenses	$16.57M	$6.761M	$15.80M
YoY Change	1482.9%		1409.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$24.64M	$18.98M	$24.64M
YoY Change	185.86%		185.86%
LONG-TERM LIABILITIES
Long-Term Debt	$75.70M	$291.0K	$75.70M
YoY Change
Other Long-Term Liabilities	$43.00K	$22.62M	$37.74M
YoY Change
Total Long-Term Liabilities	$75.74M	$22.91M	$113.4M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.64M	$18.98M	$24.64M
Total Long-Term Liabilities	$75.74M	$22.91M	$113.4M
Total Liabilities	$138.1M	$41.89M	$138.1M
YoY Change	1502.05%		1502.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$385.7M
YoY Change
Common Stock	$252.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$491.6M	$278.6M	$491.6M
YoY Change
Total Liabilities & Shareholders Equity	$629.6M	$320.5M	$629.6M
YoY Change	5273.69%		5273.69%

Cashflow Statement

Concept	2021 Q4	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$60.77M	-$829.0K	-$381.1M
YoY Change	469.95%	-72.47%	3473.77%
Depreciation, Depletion And Amortization	$12.00K	$2.000K	$34.00K
YoY Change
Cash From Operating Activities	-$56.43M	-$1.049M	-$135.1M
YoY Change	1619.81%	-71.17%	1171.02%
INVESTING ACTIVITIES
Capital Expenditures	-$64.00K	$0.00	-$186.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$63.55M	$63.44M
YoY Change
Cash From Investing Activities	-$64.00K	$0.00	$63.26M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	74.43M	$0.00	660.1M
YoY Change	5692.14%		48368.94%
NET CHANGE
Cash From Operating Activities	-56.43M	-$1.049M	-135.1M
Cash From Investing Activities	-64.00K	$0.00	63.26M
Cash From Financing Activities	74.43M	$0.00	660.1M
Net Change In Cash	17.94M	-$969.0K	588.3M
YoY Change	-998.7%	-73.37%	-6396.63%
FREE CASH FLOW
Cash From Operating Activities	-$56.43M	-$1.049M	-$135.1M
Capital Expenditures	-$64.00K	$0.00	-$186.0K
Free Cash Flow	-$56.36M	-$1.049M	-$134.9M
YoY Change		-71.17%	1169.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity File Number EntityFileNumber	001-04321
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001847903
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Registrant Name EntityRegistrantName	CENTESSA PHARMACEUTICALS PLC
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1612294
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3rd Floor
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	1 Ashley Road
CY2021	dei	Entity Address Address Line3 EntityAddressAddressLine3	Altrincham
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cheshire
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	WA14 2DT
CY2021	dei	Entity Address Country EntityAddressCountry	GB
CY2021	dei	Country Region CountryRegion	+44
CY2021	dei	City Area Code CityAreaCode	203
CY2021	dei	Local Phone Number LocalPhoneNumber	9206789
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1073339335	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94020005	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	595082000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7227000	USD
CY2021Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	15392000	USD
CY2020Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	2633000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18300000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1305000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	628774000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	11165000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	699000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552000	USD
CY2021Q4	us-gaap	Assets Assets	629635000	USD
CY2020Q4	us-gaap	Assets Assets	11717000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8065000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1032000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16573000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1047000	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5339000	USD
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	288000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	913000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24638000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8619000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	37700000	USD
CY2020Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	138081000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	8619000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6549205	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6549205	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	25521000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.002
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	22840902	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	152500000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89988228	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89988228	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	0	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	252000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	876267000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	688000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-385653000	USD
CY2020Q4	us-gaap	Members Equity MembersEquity	-22423000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	491554000	USD
CY2020Q4	cnta	Members Equity Carrying Amount Attributable To Parent MembersEquityCarryingAmountAttributableToParent	-22423000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	629635000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11717000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	95660000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	662000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9301000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4263000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42888000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	121000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1139000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	790000	USD
	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	15082000	USD
CY2021Q1	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	0	USD
CY2020	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	0	USD
CY2020	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	0	USD
CY2019	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	220454000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-374084000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-783000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-10440000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-5053000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1172000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-68000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	310000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	118000	USD
	cnta	Debt Issuance Expense DebtIssuanceExpense	1331000	USD
CY2021Q1	cnta	Debt Issuance Expense DebtIssuanceExpense	0	USD
CY2020	cnta	Debt Issuance Expense DebtIssuanceExpense	0	USD
CY2019	cnta	Debt Issuance Expense DebtIssuanceExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4370000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	155000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	105000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-380957000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-829000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10663000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5061000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-381071000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-10663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-5061000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	778000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	107000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-240000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	412000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-380293000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-722000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10903000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4649000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.07
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75166456	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75166456	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6250000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	262698000	USD
	cnta	Adjustments To Additional Paid In Capital Forgiveness Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalForgivenessOfConvertibleDebt	6199000	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	12000	USD
	cnta	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	0	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	779000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14851000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	778000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-381071000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	491554000	USD
CY2018Q4	us-gaap	Members Equity MembersEquity	-7450000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	236000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	412000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-5061000	USD
CY2019	cnta	Members Equity Net Equity Contributions MembersEquityNetEquityContributions	6000	USD
CY2019Q4	us-gaap	Members Equity MembersEquity	-11857000	USD
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	336000	USD
CY2020Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-240000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-10663000	USD
CY2020	cnta	Members Equity Net Equity Contributions MembersEquityNetEquityContributions	1000	USD
CY2020Q4	us-gaap	Members Equity MembersEquity	-22423000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	107000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	107000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	USD
CY2021Q1	us-gaap	Members Equity MembersEquity	-23145000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-381071000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-10663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-5061000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	220454000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14851000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	336000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	236000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	USD
	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	-15782000	USD
CY2021Q1	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	0	USD
CY2020	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	-186000	USD
CY2019	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	0	USD
	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	6796000	USD
CY2021Q1	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-74000	USD
CY2020	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	1456000	USD
CY2019	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	647000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16164000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-681000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-306000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1397000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4157000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-358000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-49000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	855000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12968000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	653000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	123000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	676000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-28000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	57000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	60000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135109000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1049000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10630000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5825000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	68038000	USD
CY2021Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4596000	USD
CY2021Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2019	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63256000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	241597000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	5168000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	344136000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	73930000	USD
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1361000	USD
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3831000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	283000	USD
CY2021Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	779000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9343000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3700000	USD
CY2019	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	0	USD
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	6000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	660147000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4966000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1362000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9005000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1822000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-75000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	520000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	590116000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-969000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16570000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1483000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7227000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16570000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12870000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	595082000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6258000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7227000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Stock Issued1 StockIssued1	262698000	USD
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	22618000	USD
CY2021Q1	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	0	USD
CY2020	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6250000	USD
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	6199000	USD
CY2021Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2020	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2019	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
	cnta	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	261000	USD
CY2021Q1	cnta	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	0	USD
CY2020	cnta	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019	cnta	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	0	USD
CY2021Q2	cnta	Sale Of Stock Number Of Ordinary Shares Per American Depositary Shares SaleOfStockNumberOfOrdinarySharesPerAmericanDepositaryShares	1	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	344100000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-385700000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	595100000	USD
CY2021	cnta	Cash And Cash Equivalents At Carrying Value Sufficient Funding Term CashAndCashEquivalentsAtCarryingValueSufficientFundingTerm	P12M
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.</span></div>
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3600000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of the date of the consolidated and combined financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated and combined financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, the note purchase agreement, derivative liability and contingent value rights assumptions, accrued research and development expenses, and, prior to the IPO, the fair value of the Company’s ordinary shares.</span></div>
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2021	cnta	Defined Contribution Plan Minimum Contribution Percent DefinedContributionPlanMinimumContributionPercent	0.07
CY2021	cnta	Defined Contribution Plan Minimum Employer Contribution Percent DefinedContributionPlanMinimumEmployerContributionPercent	0.03
CY2021	cnta	Defined Contribution Plan Minimum Employee Contribution Percent DefinedContributionPlanMinimumEmployeeContributionPercent	0.04
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12713326	shares
CY2021Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11224000	USD
CY2020Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	992000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4661000	USD
CY2019Q4	us-gaap	Members Equity MembersEquity	-11857000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5339000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	769000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16573000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1047000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2021Q1	us-gaap	Members Equity MembersEquity	-23145000	USD
CY2020Q4	us-gaap	Members Equity MembersEquity	-22423000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	9000	USD
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	1422000	USD
CY2020Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	298000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	993000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18300000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1305000	USD
CY2021Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9323000	USD
CY2020Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1001000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4865000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	0	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1514000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	37000	USD
CY2021Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	4450000	shares
CY2021Q2	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	288000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	5627000	USD
CY2021	cnta	Milestone Payment Percent Of Aggregate Principal Amount Issued Under The Notes MilestonePaymentPercentOfAggregatePrincipalAmountIssuedUnderTheNotes	0.30
CY2021	cnta	Milestone Payment Period MilestonePaymentPeriod	P5Y
CY2021Q4	cnta	Cumulative Payments Under Note Purchase Agreement Including Interest CumulativePaymentsUnderNotePurchaseAgreementIncludingInterest	1500000	USD
CY2021	cnta	Debt Instrument Convertible Conversion Price Discount Percentage Next Qualified Fundraising DebtInstrumentConvertibleConversionPriceDiscountPercentageNextQualifiedFundraising	0.20
CY2021	cnta	Debt Instrument Convertible Conversion Price Discount Percentage Change In Control DebtInstrumentConvertibleConversionPriceDiscountPercentageChangeInControl	0.50
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	700000	USD
	cnta	Adjustments To Additional Paid In Capital Forgiveness Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalForgivenessOfConvertibleDebt	6200000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	11100000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	10900000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	200000	USD
CY2021Q4	cnta	Common Stock Number Of Votes Ratio CommonStockNumberOfVotesRatio	1
CY2021	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12872147	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.92
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	133389	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	20026816	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6949243	shares
CY2021	cnta	Share Based Compensation Arrangement By Share Based Payment Award Percent Of Additional Shares Authorized Each Year ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfAdditionalSharesAuthorizedEachYear	0.05
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14852000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	336000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	236000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1008376	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.41
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11730382	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.07
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46400000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	536648	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3700000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11730382	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.07
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	46400000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.03
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	48600000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46400000	USD
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3700000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2021Q1	cnta	Common Stock Conversion Ratio CommonStockConversionRatio	1
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.74
CY2019Q1	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.88
CY2019Q1	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.88
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32983000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2323000	USD
CY2021Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	8734000	USD
CY2020Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6967000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1016000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2339000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49045000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2339000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	655000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-495000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30500000	USD
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets	16100000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	581000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	188000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-160000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
	cnta	Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Rd EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessRD	-0.11
CY2020	cnta	Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Rd EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessRD	0
CY2019	cnta	Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Rd EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessRD	0
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.11
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.15
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.19
	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.05
CY2020	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.28
CY2019	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.33
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.04
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.05
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.01
	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.08
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.08
CY2021	dei	Auditor Name AuditorName	KPMG LLP
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	dei	Auditor Location AuditorLocation	Boston, MA
CY2021	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001847903-22-000022-index-headers.html	Edgar Link	pending
0001847903-22-000022-index.html	Edgar Link	pending
0001847903-22-000022.txt	Edgar Link	pending
0001847903-22-000022-xbrl.zip	Edgar Link	pending
a202112311034oberlandamend.htm	Edgar Link	pending
a20211231ex1035onefederals.htm	Edgar Link	pending
a20211231ex231kpmgconsent.htm	Edgar Link	pending
a20211231ex43descriptionof.htm	Edgar Link	pending
a20211231exhibit311.htm	Edgar Link	pending
a20211231exhibit312.htm	Edgar Link	pending
a20211231exhibit321.htm	Edgar Link	pending
a20211231exhibit322.htm	Edgar Link	pending
centessa-ex1022empagmtgwei.htm	Edgar Link	pending
centessa-ex1032empagmtmtho.htm	Edgar Link	pending
centessa-ex105empagmtsaura.htm	Edgar Link	pending
cnta-20211231.htm	Edgar Link	pending
cnta-20211231.xsd	Edgar Link	pending
cnta-20211231_cal.xml	Edgar Link	unprocessable
cnta-20211231_def.xml	Edgar Link	unprocessable
cnta-20211231_g1.jpg	Edgar Link	pending
cnta-20211231_g10.jpg	Edgar Link	pending
cnta-20211231_g11.jpg	Edgar Link	pending
cnta-20211231_g12.jpg	Edgar Link	pending
cnta-20211231_g13.jpg	Edgar Link	pending
cnta-20211231_g14.jpg	Edgar Link	pending
cnta-20211231_g15.jpg	Edgar Link	pending
cnta-20211231_g16.jpg	Edgar Link	pending
cnta-20211231_g17.jpg	Edgar Link	pending
cnta-20211231_g18.jpg	Edgar Link	pending
cnta-20211231_g19.jpg	Edgar Link	pending
cnta-20211231_g2.jpg	Edgar Link	pending
cnta-20211231_g20.jpg	Edgar Link	pending
cnta-20211231_g21.jpg	Edgar Link	pending
cnta-20211231_g22.jpg	Edgar Link	pending
cnta-20211231_g23.jpg	Edgar Link	pending
cnta-20211231_g24.jpg	Edgar Link	pending
cnta-20211231_g25.jpg	Edgar Link	pending
cnta-20211231_g26.jpg	Edgar Link	pending
cnta-20211231_g27.jpg	Edgar Link	pending
cnta-20211231_g28.jpg	Edgar Link	pending
cnta-20211231_g29.jpg	Edgar Link	pending
cnta-20211231_g3.jpg	Edgar Link	pending
cnta-20211231_g30.jpg	Edgar Link	pending
cnta-20211231_g31.jpg	Edgar Link	pending
cnta-20211231_g32.jpg	Edgar Link	pending
cnta-20211231_g33.jpg	Edgar Link	pending
cnta-20211231_g34.jpg	Edgar Link	pending
cnta-20211231_g35.jpg	Edgar Link	pending
cnta-20211231_g36.jpg	Edgar Link	pending
cnta-20211231_g37.jpg	Edgar Link	pending
cnta-20211231_g38.jpg	Edgar Link	pending
cnta-20211231_g39.jpg	Edgar Link	pending
cnta-20211231_g4.jpg	Edgar Link	pending
cnta-20211231_g40.jpg	Edgar Link	pending
cnta-20211231_g41.jpg	Edgar Link	pending
cnta-20211231_g42.jpg	Edgar Link	pending
cnta-20211231_g43.jpg	Edgar Link	pending
cnta-20211231_g44.jpg	Edgar Link	pending
cnta-20211231_g45.jpg	Edgar Link	pending
cnta-20211231_g46.jpg	Edgar Link	pending
cnta-20211231_g47.jpg	Edgar Link	pending
cnta-20211231_g48.jpg	Edgar Link	pending
cnta-20211231_g49.jpg	Edgar Link	pending
cnta-20211231_g5.jpg	Edgar Link	pending
cnta-20211231_g6.jpg	Edgar Link	pending
cnta-20211231_g7.jpg	Edgar Link	pending
cnta-20211231_g8.jpg	Edgar Link	pending
cnta-20211231_g9.jpg	Edgar Link	pending
cnta-20211231_htm.xml	Edgar Link	completed
cnta-20211231_lab.xml	Edgar Link	unprocessable
cnta-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNTA
Centessa Pharmaceuticals plc Stock $cnta

2021 Q4 Form 10-K Financial Statement

#000184790322000022 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA Centessa Pharmaceuticals plc Stock $cnta

2021 Q4 Form 10-K Financial Statement

#000184790322000022 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA
Centessa Pharmaceuticals plc Stock $cnta